60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported robust financial and operational results for the full year 2025 on Tuesday, March 31, 2026, headlined by a 65% surge in net product revenue.
The company, which specializes in developing and commercializing medicines for infectious diseases, saw annual revenue climb to $1.005 million, marking its first full year surpassing the million-dollar milestone.
The company's commercial momentum was supported by several high-profile distribution and pharmacy partnerships.
During 2025, 60 Degrees Pharmaceuticals finalized agreements with GoodRx and Runway Health, significantly expanding patient access to its core product offerings.
These partnerships are central to the company’s strategy of simplifying the fulfillment process for specialty anti-infective medications.
Financially, the company reported a gross profit of approximately $223,800 for the fiscal year.
A disciplined approach to cost management led to a reduction in operating expenses, which fell to approximately $8.4 million.
This operational efficiency contributed to an improved bottom line, with the annual net loss narrowing to $7.37 million compared to previous periods.
To support its ongoing clinical and commercial scaling, the company raised approximately $4.03 million through its At-The-Market (ATM) equity facility during 2025.
Management noted that this activity exhausted the company's current shelf capacity, providing a capital cushion as it enters a catalyst-rich 2026.
On the clinical front, 60 Degrees Pharmaceuticals achieved several major milestones throughout the year.
The company successfully expanded access to treatments for relapsing babesiosis and secured a license from Yale University for certain tafenoquine-related technologies.
Additionally, the company announced the opening of a new clinical site for its Phase 2 programs, aimed at broadening the therapeutic applications of its lead compounds.